Patrick Boisseau

Patrick Boisseau is VP Europe at CEATech Healthtech Institute, based in Grenoble (France). He managed a significant number of EU collaborative projects, research infrastructures, coordination actions and networks of excellence. His expertise is in nanomedicine, drug delivery, medical imaging and innovative medical technologies. He is Chairman of the European Technology Platform on Nanomedicine and of ESTHER, the European Industry Driven Initiative on Emerging and Strategic Technologies for Healthcare, in cooperation with Medtech-Europe. he joined Medtech-Europe in 2018 as Associate Partner.

Patrick Boisseau will be a speaker at the MedTech Forum on 16/5. Find more about the programme here ! As European research and innovation funds extend their focus towards diagnostics, digital and medical technologies, medtech companies must be ready to engage. A major future EU public-private partnership in research and innovation is currently in gestation. I believe it could help to address some of the biggest challenges in modern healthcare – and its scope will be wide enough to welcome medical devices and diagnostics companies, large and small. Let’s consider some historical context. The EU research and innovation budget is significant. The Horizon 2020 programme, which ends next year, has a budget of around €80 billion. One of the key elements, as far as healthcare is concerns, has been the Innovative Medicines Initiative (IMI). This public-private partnership was funded by the European Commission and through in-kind contributions from pharmaceutical companies. In its first iteration, it had a total budget of €2 billion. The current incarnation which ends next year, has a budget of more than €3 billion. While IMI has, for more than 10 years, fostered collaboration and cooperation between pharmaceutical companies in unblocking bottlenecks in the medicines development pipeline, I expect the next big ‘PPP Health’ to go further. Modelled on the IMI structure as well as the ECSEL partnership for the micro-electronics sector, it will encompass pharma, biotech and medtech. This makes perfect sense: the solutions to the health challenges we face as a society do not lie in one industry – the future is patient-centred and integrated, with a significant role for digital technologies. I expect this approach to be welcomed by the medtech sector, particularly if it is accompanied by supports that will help start-ups and entrepreneurs tap into funds that may previously have seemed distant...